- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.11. | Invizyne Technologies selected for $2M project to advance sustainable aviation fuel capabilities | 1 | Seeking Alpha | ||
| 19.11. | Invizyne Technologies, Inc.: Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities | 1 | GlobeNewswire (USA) | ||
| INVIZYNE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 18.11. | Invizyne Technologies Inc - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | Invizyne Technologies, Inc.: Invizyne Technologies Announces Closing of Initial Public Offering | 118 | GlobeNewswire (Europe) | Monrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and... ► Artikel lesen | |
| 13.11. | Invizyne Technologies, Inc.: Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing | 130 | GlobeNewswire (Europe) | Monrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially... ► Artikel lesen | |
| 13.11. | Invizyne Technologies stock climbs 13% following $15M IPO | 6 | Seeking Alpha | ||
| 13.11. | Invizyne Technologies Opens At $11.10, IPO Priced At $8 | 5 | Investing.com | ||
| 13.11. | Invizyne Technologies, Inc.: Invizyne Technologies Begins Trading on NASDAQ | 110 | GlobeNewswire (Europe) | Monrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and... ► Artikel lesen | |
| 12.11. | Invizyne Technologies Inc - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | Invizyne Technologies, Inc.: Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024 | 83 | GlobeNewswire (Europe) | Monrovia, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and... ► Artikel lesen | |
| 12.11. | Biomanufacturing company Invizyne Technologies prices IPO at $8 | 5 | Renaissance Capital | ||
| 12.11. | Invizyne Technologies prices $15M U.S. IPO | 7 | Seeking Alpha | ||
| 21.10. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 05.10. | Invizyne Cuts IPO Size And Lifts Offering Price | 1.151 | AFX News | WASHINGTON (dpa-AFX) - Invizyne Technologies announced that it has decreased the size of shares and increased the price range of its planned initial public offering.The company, which develops... ► Artikel lesen | |
| 05.10. | Biomanufacturing company Invizyne Technologies increases range and decreases shares ahead of $15 IPO deal size | 3 | Renaissance Capital | ||
| 04.10. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 4 | SEC Filings | ||
| 19.09. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 4 | SEC Filings | ||
| 07.09. | Biomanufacturing company Invizyne Technologies cuts share offering by 13% and adds rights ahead of $15 million IPO | 1 | Renaissance Capital | ||
| 06.09. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 01.08. | Invizyne Technologies Inc - 8-A12B, Registration of securities | - | SEC Filings |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,015 | +0,27 % | Qiagen NV-Aktie läuft heute schlechter (42,62 €) | Im Minus liegt aktuell der Anteilsschein von Qiagen NV . Die Aktie kostete zuletzt 42,62 Euro. Am Aktienmarkt hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,62 Prozent verbilligt.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | +3,93 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| EVOTEC | 8,410 | +0,06 % | Bayer, Evotec, Nel ASA, NVIDIA, Rheinmetall, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CSL | 168,46 | +0,26 % | Why CSL and these excellent ASX retirement shares could be buys in 2025 | ||
| TEMPUS AI | 34,650 | -0,74 % | Tempus AI (NASDAQ:TEM) Shares Down 5.7% Following Insider Selling | ||
| BIONTECH | 108,90 | -0,27 % | BioNTech-Aktie: Deshalb kommt sie unter die Räder | Am blutroten Mittwoch an den Märkten ist auch die BioNTech-Aktie nicht verschont geblieben, sondern um fast -5% auf 111,61 US$ abgerutscht. Ist das nur dem Umfeld geschuldet oder gibt es spezielle Gründe?... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 685,60 | -0,20 % | Regeneron Pharma: Phase 3 Trial With EYLEA HD 8 Mg Meets Primary Endpoint | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD or aflibercept injection 8 mg... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,940 | +1,50 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BB BIOTECH | 37,550 | -0,92 % | BB Biotech Erkenntnisse beim Lunch mit Vorständen | Ich war wie versprochen beim Investorenlunch von BB Biotech. Der scheidende Vorstandssprecher Dr. Daniel Koller führte seinen Nachfolger Dr. Christian Koch ein. Wie jedes Jahr hielt Vorstandssprecher... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,390 | -1,97 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| EDGEWISE THERAPEUTICS | 29,660 | -0,94 % | Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains | ||
| 180 LIFE SCIENCES | 2,740 | +48,11 % | 180 Life Sciences Corp. - S-1/A, General form for registration of securities | ||
| JANUX THERAPEUTICS | 56,13 | -1,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 36,810 | -1,50 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 11,450 | +2,42 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies |
Das Unternehmen INVIZYNE TECHNOLOGIES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 19,010 Euro und damit -1,81 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVIZYNE TECHNOLOGIES INC finden Sie auf Wallstreet Online.
